Well Referenced

Tag: melanocortin receptor agonists

The future is today: emerging drugs for the treatment of erectile dysfunction

This review explores emerging drug therapies for erectile dysfunction (ED), discussing both central regulators (clavulanic acid, dopamine and melanocortin receptor agonists) and peripheral regulators (novel PDE5 inhibitors, soluble and particulate guanylyl cyclase activators, rho-kinase inhibitors, and maxi-K channel openers). These emerging treatments offer the potential for individualized approaches tailored to

Read More »
June 26, 2025 No Comments

Emerging drugs for the treatment of erectile dysfunction

This review article explores emerging pharmacological and regenerative therapies for erectile dysfunction (ED), including soluble guanylate cyclase (sGC) activators and stimulators, Rho-kinase inhibitors, melanocortin receptor agonists, gene therapy, and stem cell therapy. These treatments offer alternative mechanisms beyond phosphodiesterase type 5 (PDE5) inhibitors, potentially benefiting patients unresponsive to conventional ED

Read More »
June 26, 2025 No Comments

Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: results from basic research and clinical studies

This systematic review examines the therapeutic potential of melanocortin receptor (MCR) agonists, such as melanotan I, melanotan II, and bremelanotide, in treating sexual dysfunction in both men and women. These agents act on central melanocortin pathways, differentiating them from traditional treatments like phosphodiesterase type 5 inhibitors. Clinical and preclinical studies

Read More »
June 26, 2025 No Comments